For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
21
views
13
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      422
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. However, such regimens of shorter duration trastuzumab therapy like FinHer, offered in view of economic constraints, may not be able to achieve globally comparable cure rates in early breast cancer especially with high-risk women with more than 3 lymph node positive.

          Methods and Material:

          Outcome of 21 patients with HER2 positive breast cancer was treated with short course trastuzumab combination chemotherapy in the adjuvant setting was studied.

          Results:

          Out of 21 patients 15 are alive and disease free with a follow up of up to 73 months (median follow up 42 months).

          Related collections

          Most cited references13

          • Record: found
          • Abstract: found
          • Article: not found

          Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India.

          Sudip Ghosh, S. Gupta, S S Desai … (2015)
          This study was undertaken to document the pattern of expression of estrogen (ER), progesterone (PR) and human epidermal growth factor receptor-2 (HER2) and the usage of HER2-targeted therapy in a large tertiary care hospital in India in the year 2008. The histopathology reports of all breast cancer patients registered in the hospital in 2008 were extracted from the electronic medical record system. All the cases were immunohistochemically evaluated for estrogen and progesterone receptor status (ER and PR), and c-erbB-2 protein (HER2) expression using standard immunoperoxidase method. The use of HER2-targeted therapies was evaluated by extracting relevant information from the database of the hospital pharmacy and case charts of patients enrolled in ongoing approved trials. A total of 2001 new patients of invasive breast cancers with available pathology reports were registered in the hospital in the year 2008. ER and/or PR expression was positive in tumors of 1025 (51.2%) patients. HER2 3+ expression by immunohistochemistry (IHC) was found in 335 (16.7%) and HER2 2+ in 163 (8.1%). The triple negative phenotype was found in 596 (29.8%) patients. An estimated 441 patients were eligible to receive HER2-targeted therapy based on their HER2 status. Of these 38 (8.6%) patients received some form of HER2-targeted therapy; 20 patients (4.5%) as part of ongoing clinical trials and 18 (4.1%) as part of routine care. The overwhelming majority of patients eligible for HER2-targeted therapy in our institution are unable to receive it because of financial constraints and limited access to health insurance. There is a higher fraction of patients with the triple negative phenotype compared to the Western population.
          Article 0 comments Cited 31 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer.

            P. M. Parikh, S. Gupta, S. Dawood … (2014)
            The management of hormone receptor-positive Her2-negative breast cancer patients with advanced or metastatic disease is a common problem in India and other countries in this region. This expert group used data from published literature, practical experience, and opinion of a large group of academic oncologists, to arrive at practical consensus recommendations for use by the community oncologists.
            Article 0 comments Cited 12 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

              S F Dent, S. Gandhi, M Mates … (2015)
              This systematic review addresses the question "What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer?"
              Article 0 comments Cited 11 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): South Asian J Cancer
                Journal ID (iso-abbrev): South Asian J Cancer
                Journal ID (publisher-id): SAJC
                Title: South Asian Journal of Cancer
                Publisher: Medknow Publications & Media Pvt Ltd (India )
                ISSN (Print): 2278-330X
                ISSN (Electronic): 2278-4306
                Publication date (Print): Apr-Jun 2017
                Volume: 6
                Issue: 2
                Pages: 47-50
                Affiliations
                [1]Department of Oncology, Deenanath Mangeshkar Hospital and Research Centre, Pune, India
                [1 ]Department of Oncology, Asian Institute of Oncology, Mumbai, Maharashtra, India
                [2 ]Department of Oncology, Kovai Medical Centre and Hospital, Coimbatore, Tamil Nadu, India
                Author notes
                Correspondence to: Dr. Sachin S. Hingmire, E-mail: sshingmire@ 123456yahoo.com
                Article
                Publisher ID: SAJC-6-47
                DOI: 10.4103/sajc.sajc_68_17
                PMC ID: 5506806
                SO-VID: 7b1b736f-0862-4c7f-9e5f-e4a5534d3c72
                Copyright © Copyright: © 2017 The South Asian Journal of Cancer
                License:

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

                History
                Categories
                Subject: ORIGINAL ARTICLE: Breast Cancer

                Keywords: finher,short course trastuzumab,survival
                Data availability:
                Keywords: finher, short course trastuzumab, survival

                Comments

                Comment on this article